FDA ta ba da sunayen magungunan marayu ga CART T-Cell Therapy A2B530 don maganin ciwon daji na colorectal

FDA ta ba da sunayen magungunan marayu ga CART T-Cell Therapy A2B530 don maganin ciwon daji na colorectal

Share Wannan Wallafa

A watan Maris 2024, wata sanarwa da aka fitar ta ce A2B530 (A2 Biotherapeutics), CAR T-cell therapy, an bai wa Marayu Drug Designation don magance ciwon daji na colorectal wanda ke bayyana antigen carcinoembryonic (CEA) kuma ya rasa HLA-A * 02 magana a cikin mutanen da ke da germline. Heterozygous HLA-A*02(+) cuta.

Masu bincike suna tunanin cewa maganin ƙwayar cuta na autologous-gated cell far na iya kai hari ga ƙwayoyin tumo yayin da yake kare lafiyayyen nama. Wannan saboda yana da ginanniyar canjin aminci wanda zai iya kiyaye lafiyayyen nama daga yin rauni. A cikin binciken 1/2 EVEREST-1 (NCT05736731), za a gwada wannan ra'ayin.

Kuna so karanta: CAR T-Cell far a China

Shawarar da FDA ta yanke na ba Marayu Drug Designation ya tabbatar da babbar buƙatar da ba ta cika ba don ingantattun jiyya ga masu fama da cutar. ciwon daji, in ji William Go, MD, PhD, babban jami'in kula da lafiya na A2 Bio, a cikin wata sanarwa. Wannan nadi yana ƙarfafa alƙawarin mu na yin amfani da dandamalin fasaha na zamani don ƙirƙirar sabon ciwon daji jiyya ga mutanen da ciwon daji ke da wuyar magance su.

Alamar buɗewa, lokaci 1/2 EVEREST-1 binciken yana kallon A2B530 a matsayin mai yiwuwa magani ga ciwace-ciwacen ciwace-ciwacen daji kamar ciwon daji na launi, ciwon daji na pancreatic, da cututtukan daji na kansa marasa kansar. Hakanan yana duban wasu nau'ikan ciwace-ciwacen ciwace-ciwacen da ke haifar da CEA amma ba HLA-A*02 ba. Mutanen da ke cikin binciken EVEREST-1 yanzu sun kasance na farko a cikin binciken BASECAMP-1 (NCT04981119), inda aka tattara ƙwayoyin T su, sarrafa su, kuma a ajiye su don amfani da su daga baya.

Kuna so karanta: CAR T-Cell far don Multi myeloma a China

Babban burin binciken lokaci na 1 shine don nemo mafi aminci kuma mafi inganci kashi. Dole ne a kiyaye aminci da inganci a matsayin manyan manufofin binciken lokaci na 2. Adadin m tumo Kwayoyin da shawarar da aka ba da shawarar za su iya kashe yayin da suke adana ƙwayoyin lafiya.

Ciwon daji mai launi, wanda shine kalma ga duka biyu ciwon hanji da dubura, yana faruwa ne lokacin da polyps (rukunin sel da ke girma tare) suka fito a cikin hanji ko dubura kuma suka zama ciwon daji. Tsufa, baƙar fata, ciwon tarihin polyps ko ciwon daji a cikin jikin ku ko a cikin dangin ku, cututtukan hanji mai kumburi, kwayoyin halitta, ciwon sukari, kiba, cin abinci na yamma, da shan taba da shan duk abubuwan da ke jefa mutane cikin haɗari.

Tiyata, radiation, maganin da aka yi niyya, da immunotherapy su ne mafi yawan hanyoyin magance ciwon daji na colorectal. Duk da haka, da yawa daga cikin hanyoyin da ake amfani da su na yanzu don wannan ciwon daji da sauran masu ciwon ciwace-ciwace na iya kashe marasa lafiya.

Kuna so karanta: Farashin CAR T Cell a China

Masu binciken da suka yi aiki a kan binciken sunyi tunanin wannan CAR T-cell far ya fi sauran jiyya da aka yi niyya. Wannan saboda CAR T-kwayoyin kashe ƙwayoyin ƙwayar cuta ba tare da cutar da ƙwayoyin lafiya ba saboda suna da ginanniyar canjin aminci wanda ke kiyaye lafiyayyen nama daga yin rauni.

Biyan kuɗi zuwa ga Newsletter

Sami sabuntawa kuma kada ku rasa bulogi daga Cancerfax

Toarin Don Bincika

Lutetium Lu 177 dotatate an amince da shi ta USFDA don marasa lafiya na yara masu shekaru 12 da haihuwa tare da GEP-NETS
Cancer

Lutetium Lu 177 dotatate an amince da shi ta USFDA don marasa lafiya na yara masu shekaru 12 da haihuwa tare da GEP-NETS

Lutetium Lu 177 dotatate, magani mai ban sha'awa, kwanan nan ya sami izini daga Hukumar Abinci da Magunguna ta Amurka (FDA) ga marasa lafiya na yara, wanda ke nuna gagarumin ci gaba a cikin ilimin cututtukan cututtukan yara. Wannan amincewar tana wakiltar alamar bege ga yara masu fama da ciwace-ciwacen ƙwayoyin cuta na neuroendocrine (NETs), nau'in ciwon daji da ba kasafai ba amma ƙalubale wanda galibi ke tabbatar da juriya ga hanyoyin warkewa na al'ada.

USFDA ta amince da Nogapendekin alfa inbakicept-pmln don cutar kansar mafitsara mara tsoka da BCG.
Ciwon daji na bladder

USFDA ta amince da Nogapendekin alfa inbakicept-pmln don cutar kansar mafitsara mara tsoka da BCG.

“Nogapendekin Alfa Inbakicept-PMLN, wani labari na rigakafi, yana nuna alƙawarin magance cutar kansar mafitsara idan aka haɗa shi da maganin BCG. Wannan sabuwar dabarar ta shafi takamaiman alamomin cutar kansa yayin da ake ba da amsa ga tsarin rigakafi, yana haɓaka ingancin jiyya na gargajiya kamar BCG. Gwajin gwaje-gwaje na asibiti suna bayyana sakamako masu ƙarfafawa, yana nuna ingantattun sakamakon haƙuri da yuwuwar ci gaba a cikin sarrafa kansar mafitsara. Haɗin kai tsakanin Nogapendekin Alfa Inbakicept-PMLN da BCG yana sanar da sabon zamani a cikin maganin cutar kansar mafitsara."

Ana buƙatar taimako? Ourungiyarmu a shirye take don taimaka muku.

Muna fatan samun lafiya cikin sauri na masoyinku da na kusa.

Fara hira
Muna Kan layi! Yi Taɗi da Mu!
Duba lambar
Hello,

Barka da zuwa CancerFax!

CancerFax wani dandali ne na majagaba wanda aka keɓe don haɗa mutane da ke fuskantar ciwon daji na zamani tare da hanyoyin kwantar da hankali kamar CAR T-Cell far, TIL far, da gwaji na asibiti a duk duniya.

Bari mu san abin da za mu iya yi muku.

1) Maganin ciwon daji a kasashen waje?
2) CAR T-Cell far
3) rigakafin cutar daji
4) Shawarar bidiyo ta kan layi
5) Maganin Proton